ClinicalTrials.gg
CompletedNCT06786455Updated Dec 18, 2025

Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical Study

A Phase 2 interventional study of SHR-1905 Injection in Adolescent Asthma, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 6 under way, 2 of them phase 3. Asthma · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
14th of 15
9 · median 84
Started
2025
with 3 others
Phase 2
6 of 15
3 open now
Registered
11th of 15
by date

Among the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., this one is the 14th largest by enrollment, is one of 4 that started in 2025, is one of 6 in phase 2, and was the 11th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy of subcutaneous injection of SHR-1905 in adolescent asthmatic subjects - an open-label, single-dose Phase II clinical study

03

Conditions studied

  • Adolescent Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The age of signing the must be ≥12 years old and \<18 years old, both male and female.
  2. Body weight ≥30 kg and ≥18 kg/m2.
  3. The clinical diagnosis was asthma for at least 6 months.
  4. Subjects receiving asthma maintenance therapy were required to maintain a stable dose for 4 weeks prior to baseline.
  5. / estimated value of pre-BD before bronchodilator in screening period must be ≥40%.
  6. Screening period bronchial dilation test or bronchial excitation test positive.
  7. Informed consent was signed before the trial.
  8. Potentially fertile subjects voluntarily take appropriate measures.

Exclusion criteria

Exclusion Criteria:

  1. Combined with lung disease other than asthma
  2. A combination of diseases other than asthma that may affect lung function
  3. Combined with other pulmonary or systemic diseases associated with eosinophil elevation, or other diseases associated with eosinophil elevation that the investigators believe need to be excluded.
  4. Bronchial thermoplasty or bronchial cryoablation were performed within 1 year prior to baseline.
  5. Acute asthma attacks requiring systemic use for ≥3 days occurred within 1 month prior to baseline.
  6. Systemic glucocorticoids were used as maintenance therapy for the first 3 months of the baseline period.
  7. Acute episodes of life-threatening asthma occurred within 5 years prior to baseline.
  8. Allergen immunotherapy was administered 8 weeks prior to baseline.
  9. Non-selective beta-blockers were used for the first 4 weeks of the baseline period.
  10. Participated in clinical trials of any drug or medical device within 12 weeks prior to screening.
  11. Severe trauma or major surgery in the 6 months prior to baseline.
  12. History of malignant tumor.
  13. Combined with serious other systemic diseases.
  14. Combined with immunodeficiency disease.
  15. A history of infection requiring treatment with systemic anti-infective drugs in the 4 weeks prior to baseline.
  16. Parasitic infection was present in the 6 months prior to baseline.
  17. Abnormal laboratory tests during screening or baseline. Screening or baseline results were abnormal and clinically significant.
  18. At the time of screening, smokers were still smoking or had quit for less than 6 months, or had a smoking history of ≥10 pack-years.
  19. Alcohol consumption within 1 month prior to baseline.
  20. History of drug abuse and drug use within 1 year before screening.
  21. Those who had a history of blood donation within 4 weeks prior to baseline, or had significant blood loss, or had received a blood transfusion within 8 weeks.
  22. People who received live (attenuated) vaccine or viral vector vaccine within 8 weeks prior to the baseline period or planned to receive it during the trial.
  23. Researchers and relevant staff of research centres or others directly involved in programme implementation.
  24. The investigator considers that there are any circumstances that may cause subjects to be unable to complete the study or present a significant risk to subjects or other factors that may reduce the likelihood of enrollment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    SHR-1905 Injection

    Drug: SHR-1905 Injection

Interventions

  • SHR-1905 Injection,medium dose, administered by subcutaneous injection;

06

What researchers measure

Primary outcomes

  1. PK index: Serum SHR-1905 concentration。

    Time frame: Day 253

  2. PK index: Area under the plasma concentration versus time curve (AUC)。

    Time frame: Day 253

  3. PK index: Peak Plasma Concentration (Cmax)。

    Time frame: Day 253

  4. safety: Incidence and severity of any adverse events。

    Time frame: Day 253

Secondary outcomes

  1. PD index: Change of peripheral blood eosinophils absolute value (EOS) from baseline.

    Time frame: Day 253

  2. Initial efficacy measures: Changes in forced expiratory volume in the first second (FEV1) from baseline.

    Time frame: Day 253

  3. Initial efficacy measures: Changes in exhaled nitric oxide (FeNO) from baseline.

    Time frame: Day 253

07

Study locations

1 site
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510030, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Dec 2025, 10 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 10 months is below that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jan 22, 2025
StartActual
Jan 23, 2025
Primary completionActual
Dec 3, 2025
CompletionActual
Dec 3, 2025
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06786455
Responsible party
Sponsor
First posted
Jan 22, 2025
Start date
Jan 23, 2025
Primary completion
Dec 3, 2025
Completion
Dec 3, 2025
Last update
Dec 18, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1905

Start the discussion